Table 4.
AOFAS scores of two study groups in different follow-up periods.
| Measurements | Total | Group | P1 | |
|---|---|---|---|---|
| PrT | PRP | |||
| AOFAS_0 | 34.71±17.80 (a) | 38.48±18.02 (a) | 30.09±16.79 (a) | 0.101 |
| AOFAS_21 days | 65.51±11.73 (b) | 67.52±11.23 (b) | 63.05±12.12 (b) | 0.187 |
| AOFAS_3 months | 79.35±9.99 (c) | 79.59±11.33 (c) | 79.05±8.31 (c) | 0.851 |
| AOFAS_6 months | 85.14±9.34 (d) | 85.44±10.69 (d) | 84.77±7.6 (d) | 0.805 |
| AOFAS_12 months | 88.69±12.38 (e) | 89.44±13.93 (e) | 87.77±10.42 (d) | 0.643 |
| P2 | <0.001 | <0.001 | <0.001 | |
ANOVA was used for repeated measures. Means with the same letters (in the same column) are not statistically different, P1 – between-subject effect, P2 – within-subject effect. AOFAS scores of the 2 groups also significantly improved compared to pretreatment values, and there was no significant difference between the 2 groups at the follow-up periods.